Efficacy, safety, tolerability, and pk of the hdac inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (hcc): Phase II shelter study
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.